12 Month Price Forecast For JAZZ
Distance to JAZZ Price Forecasts
JAZZ Price Momentum
🤔 Considering Jazz Pharmaceuticals (JAZZ)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 8:58 AM UTC
JAZZ Analyst Ratings & Price Targets
Based on our analysis of 26 Wall Street analysts, JAZZ has a consensus that is bullish. The median price target is $182.00, with forecasts ranging from $128.00 to $230.00. Currently, there are 17 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
With JAZZ currently trading at $120.84, the median price forecast suggests a 50.6% upside. The most optimistic forecast comes from Annabel Samimy at Stifel, projecting a 90.3% upside, while at provides the most conservative target, suggesting a 5.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
JAZZ Analyst Consensus
JAZZ Price Target Range
Latest JAZZ Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for JAZZ.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 12, 2024 | Piper Sandler | David Amsellem | Overweight | Reiterates | $163.00 |
| Dec 12, 2024 | RBC Capital | Gregory Renza | Outperform | Reiterates | $179.00 |
| Dec 12, 2024 | Needham | Ami Fadia | Buy | Reiterates | $207.00 |
| Dec 10, 2024 | RBC Capital | Gregory Renza | Outperform | Reiterates | $179.00 |
| Nov 22, 2024 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $200.00 |
| Nov 21, 2024 | Needham | Ami Fadia | Buy | Reiterates | $207.00 |
| Nov 21, 2024 | Piper Sandler | David Amsellem | Overweight | Reiterates | $163.00 |
| Nov 18, 2024 | Baird | Joel Beatty | Outperform | Maintains | $162.00 |
| Nov 7, 2024 | TD Cowen | Buy | Maintains | $195.00 | |
| Nov 7, 2024 | Needham | Ami Fadia | Buy | Reiterates | $207.00 |
| Oct 23, 2024 | RBC Capital | Gregory Renza | Outperform | Maintains | $179.00 |
| Oct 4, 2024 | RBC Capital | Gregory Renza | Outperform | Maintains | $175.00 |
| Sep 10, 2024 | Needham | Ami Fadia | Buy | Reiterates | $205.00 |
| Sep 9, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $140.00 |
| Aug 19, 2024 | JP Morgan | Jessica Fye | Overweight | Maintains | $202.00 |
| Aug 1, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $140.00 |
| Aug 1, 2024 | Needham | Ami Fadia | Buy | Maintains | $205.00 |
| Aug 1, 2024 | RBC Capital | Gregory Renza | Outperform | Maintains | $174.00 |
| Aug 1, 2024 | Baird | Joel Beatty | Outperform | Maintains | $154.00 |
| Aug 1, 2024 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $200.00 |
Stocks Similar to Jazz Pharmaceuticals PLC
The following stocks are similar to Jazz Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Jazz Pharmaceuticals PLC (JAZZ) Financial Data
Jazz Pharmaceuticals PLC has a market capitalization of $7.34B with a P/E ratio of 17.2x. The company generates $3.99B in trailing twelve-month revenue with a 11.6% profit margin.
Revenue growth is +8.5% quarter-over-quarter, while maintaining an operating margin of +24.7% and return on equity of +12.1%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Jazz Pharmaceuticals PLC (JAZZ) Company Overview
About Jazz Pharmaceuticals PLC
Develops and commercializes pharmaceutical products.
The company identifies, develops, and commercializes pharmaceutical products aimed at addressing unmet medical needs across various therapeutic areas, such as neurology, oncology, and rare diseases. Its revenue primarily comes from the sales of its marketed products, which include Xywav, Xyrem, and Epidiolex, among others, as well as from licensing and collaboration agreements that enhance its research capabilities and product pipeline.
Founded in 2003 and headquartered in Dublin, Ireland, the company has a diverse portfolio of therapies and ongoing development programs targeting critical health issues. Its strategic partnerships with other biotech firms help foster innovation and expand its product offerings in specialized medical markets.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
2,800
CEO
Mr. Bruce C. Cozadd
Country
Ireland
IPO Year
2007
Website
www.jazzpharma.comJazz Pharmaceuticals PLC (JAZZ) Latest News & Analysis
Small biotech stocks have declined, with the SPDR® S&P Biotech ETF down over 15% in ten weeks, creating lower entry points. Notable insider purchases have been observed in three small and mid-cap biotech firms.
Recent declines in small biotech stocks present potential buying opportunities, especially with insider purchases signaling confidence in select companies within the sector.
3 Oversold Biotech Names
10 days agoHigh beta sectors, including small caps and biotech, declined as the 10-Year Treasury yield exceeded 4.75%. The JP Morgan Healthcare event may improve biotech sentiment this week.
Rising Treasury yields often pressure high-beta sectors like small caps and biotech. The JP Morgan Healthcare event may reverse sentiment, presenting potential buying opportunities in oversold biotech stocks.
Jazz Pharmaceuticals' stock rose after its 3Q24 report and FDA approval of zanidatamab. Despite challenges in narcolepsy, growth in oncology and other franchises supports Vision 2025 sales goals.
Jazz Pharmaceuticals' stock rise indicates market confidence in its oncology growth and FDA approval of zanidatamab, despite challenges in its narcolepsy segment, signaling potential for future gains.
Bruce Cozadd, CEO of Jazz Pharmaceuticals, will retire by end of 2025 after appointing a successor. He will remain as Chairperson. The company projects over $4 billion in revenue for 2024.
Cozadd's planned retirement introduces leadership uncertainty, potentially impacting company strategy and investor confidence during the transition as revenue growth targets approach.
Jazz Pharmaceuticals will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference on December 17, 2024.
Jazz Pharmaceuticals' webcast at a major healthcare conference highlights its strategic direction and potential growth, influencing investor sentiment and stock performance.
Stocks DIS, LDOS, RF, FTNT, and JAZZ are highlighted for their high return on equity (ROE) as markets face increased volatility.
High ROE stocks like DIS, LDOS, RF, FTNT, and JAZZ may offer stability and potential returns during market volatility, attracting investor interest for risk management.
Frequently Asked Questions About JAZZ Stock
What is Jazz Pharmaceuticals PLC's (JAZZ) stock forecast for 2025?
Based on our analysis of 26 Wall Street analysts, Jazz Pharmaceuticals PLC (JAZZ) has a median price target of $182.00. The highest price target is $230.00 and the lowest is $128.00.
Is JAZZ stock a good investment in 2025?
According to current analyst ratings, JAZZ has 17 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $120.84. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for JAZZ stock?
Wall Street analysts predict JAZZ stock could reach $182.00 in the next 12 months. This represents a 50.6% increase from the current price of $120.84. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Jazz Pharmaceuticals PLC's business model?
The company identifies, develops, and commercializes pharmaceutical products aimed at addressing unmet medical needs across various therapeutic areas, such as neurology, oncology, and rare diseases. Its revenue primarily comes from the sales of its marketed products, which include Xywav, Xyrem, and Epidiolex, among others, as well as from licensing and collaboration agreements that enhance its research capabilities and product pipeline.
What is the highest forecasted price for JAZZ Jazz Pharmaceuticals PLC?
The highest price target for JAZZ is $230.00 from Annabel Samimy at Stifel, which represents a 90.3% increase from the current price of $120.84.
What is the lowest forecasted price for JAZZ Jazz Pharmaceuticals PLC?
The lowest price target for JAZZ is $128.00 from at , which represents a 5.9% increase from the current price of $120.84.
What is the overall JAZZ consensus from analysts for Jazz Pharmaceuticals PLC?
The overall analyst consensus for JAZZ is bullish. Out of 26 Wall Street analysts, 17 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $182.00.
How accurate are JAZZ stock price projections?
Stock price projections, including those for Jazz Pharmaceuticals PLC, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
